Relieves urinary frequency urgency Oral epinephrine-affected astigtor vibegron Phase 2 results were positive

Urovant Sciences recently announced that vibegron, an oral β-3 epinephrine-infested agonist developed by the company, has been positive in Phase 2 clinical trials for the treatment of bladder hyperactive disorder (OAB). The findings were also published in the journal European Urology.
OAB is manifested in sudden urination needs and increased frequency of urination, and some patients may experience urination leakage. At present, the cause of OAB is not clear. In the United States, about 30 million people over the age of 40 suffer from OAB symptoms that can lead to anxiety, depression, and negative impact on quality of life.
, developed by Urovant, is a small molecule that is β-3 adrenaline-per-adrenaline-infested agitant once a day. β-3 epinephrine is the most common and adrenaline β smooth muscles. Studies have shown that selective activation of β-3 epinephrine ligands can lead to smooth muscle throbbing, which can increase bladder capacity and reduce OAB symptoms.
In this randomized double-blind, placebo-controlled international phase 2b clinical trial of more than 1,300 OAB patients, patients received different doses of vibegron (3 mg, 15 mg, 50 mg, or 100 mg), totroding reseeding capsules or placebos at the first 8 weeks. Over the next 4 weeks, patients were randomly treated with vibegron (100 mg), totroding, vibegron (100 mg) and totroding, and placebo.
test results showed that in patients who used a dose of vibegron of 50 mg or 100 mg for the first 8 weeks, the daily urination, urination, urination and other indicators of OAB symptoms were significantly lower than those in the placebo group. Furthermore, patients taking a dose of 50 mg or 100 mg vibegron received a significant improvement in OAB symptom indicators after 2 weeks of treatment. Test data from the last four weeks showed that vibegron had the same effect as the previous eight weeks. At the same time vibegron shows good safety and tolerance.
, vibegron is currently in Phase 3 clinical trials. We wish this new drug well developed and soon to be available to relieve symptoms for OAB patients. (Bio Valley)